. Author manuscript; available in PMC: 2016 Nov 15.

Published in final edited form as: Gynecol Oncol. 2010 Apr 2;117(3):497–504. doi: 10.1016/j.ygyno.2010.02.021

Table 3.

Randomized phase III studies of bevacizumab in nonovarian cancers.

Author	Study	Disease site	n	Experimental arm	Bevacizumab dose/schedule
Allegra 2009²⁰	NSABP C08	mCRC	2710	FOLFOX/bevacizumab	5 mg/kg q2w
Reck 2009²¹	AVAiL	NSCLC	1043	Cisplatin/gemcitabine/bevacizumab dose 1 Cisplatin/gemcitabine/bevacizumab dose 2	7.5 mg/kg q3w 15 mg/kg q3w
Saltz 2008²²	XELOX-1/NO16996	mCRC	1401	XELOX or FOLFOX/bevacizumab	7.5 mg/kg q3w
Escudier 2008⁸	AVOREN	mRCC	649	IFN-alpha-2a/bevacizumab	10 mg/kg q2w
Miller 2007⁷	E2100	MBC	722	Weekly taxol/bevacizumab	10 mg/kg q2w
Giantonio 2007²³	E3200	mCRC	829	FOLFOX/bevacizumab	10 mg/kg q2w
Sandler 2006⁶	E4599	NSCLC	878	Carboplatin/taxol/bevacizumab	15 mg/kg q 3w
Hurwitz 2004⁵		mCRC	923	IFL/bevacizumab	5 mg/kg q2w
Miller 2005²⁴		MBC	462	Capecitabine/bevacizumab	15 mg/kg 13w

IFL=irinotecan, 5-fluorouracil and leucovorin; IFN=interferon; XELOX=oxaliplatin and capecitabine; FOLFOX=5-fluorouracil, oxaliplatin, and leucovorin.